Page 99 - 《中国药房》2024年13期

DI P P，HU Y F，MENG X S，et al. Excavation for adverse [16] VERCAUTEREN M，TRENSZ F，PASQUALI A，et al.
events signals of atezolizumab[J]. China Pharm，2022，33 Endothelin ET A receptor blockade，by activating ETB re-
（24）：3025-3028，3033. ceptors，increases vascular permeability and induces exag‐
[ 6 ] 黄玲，王凤玲，陈力，等. 基于美国FAERS数据库的利培 gerated fluid retention[J]. J Pharmacol Exp Ther，2017，
酮不良事件信号挖掘与分析[J]. 中国药房，2023，34（3）： 361（2）：322-333.
350-354. [17] VILAS-BOAS V，GIJBELS E，LEROY K，et al. Primary
HUANG L，WANG F L，CHEN L，et al. Mining and human hepatocyte spheroids as tools to study the hepato‐
analysis of risperidone adverse event signals based on toxic potential of non-pharmaceutical chemicals[J]. Int J
FAERS database[J]. China Pharm，2023，34（3）：350-354. Mol Sci，2021，22（20）：11005.
[ 7 ] WU B，LUO M，WU F B，et al. Acute kidney injury as- [18] LATTANZIO M，FERRARI M，MARTINI S，et al. Phar‐
sociated with remdesivir：a comprehensive pharmacovi- macological counseling in hepatotoxicity induced by maci‐
gilance analysis of COVID-19 reports in FAERS[J]. Front tentan and selexipag：a case report[J]. J Med Case Rep，
Pharmacol，2022，13：692828. 2022，16（1）：385.
[ 8 ] MAZHAR F，BATTINI V，GRINGERI M，et al. The im‐ [19] SIDHARTA P N，LINDEGGER N，ULČ I，et al. Pharma‐
pact of anti-TNFα agents on weight-related changes：new cokinetics of the novel dual endothelin receptor antagonist
insights from a real-world pharmacovigilance study using macitentan in subjects with hepatic or renal impairment
the FDA adverse event reporting system （FAERS） data‐ [J]. J Clin Pharmacol，2014，54（3）：291-300.
base[J]. Expert Opin Biol Ther，2021，21（9）：1281-1290. [20] BANSAL S，PRASAD A，LINAS S. Right heart failure-
[ 9 ] SKRIDE A，SABLINSKIS K，LEJNIEKS A，et al. Cha- unrecognized cause of cardiorenal syndrome[J]. J Am Soc
racteristics and survival data from Latvian pulmonary hy‐ Nephrol，2018，29（7）：1795-1798.
pertension registry：comparison of prospective pulmonary [21] CHUNG E Y M，BADVE S V，HEERSPINK H J L，et al.
hypertension registries in Europe[J]. Pulm Circ，2018，8 Endothelin receptor antagonists in kidney protection for
（3）：2045894018780521. diabetic kidney disease and beyond? [J]. Nephrology，
[10] LING Y，JOHNSON M K，KIELY D G，et al. Changing 2023，28（2）：97-108.
demographics，epidemiology，and survival of incident pul‐ [22] CALDARONE F，GEBHARDT P，HOEPER M M，et al.
monary arterial hypertension：results from the pulmonary Metacognitions in patients with frequent mental disorders
hypertension registry of the United Kingdom and Ireland after diagnosis of pulmonary arterial hypertension[J].
[J]. Am J Respir Crit Care Med，2012，186（8）：790-796. Front Psychiatry，2022，13：812812.
[11] PULIDO T，ADZERIKHO I，CHANNICK R N，et al. Ma‐ [23] QIAN Y L，QUAN R L，CHEN X X，et al. Clinical fea‐
citentan and morbidity and mortality in pulmonary arterial tures and long-term survival in idiopathic pulmonary arte‐
hypertension[J]. N Engl J Med，2013，369（9）：809-818. rial hypertension with thyroid dysfunction：insights from a
[12] SITBON O，COTTIN V，CANUET M，et al. Initial combi‐ national multicentre prospective study[J]. ERJ Open Res，
nation therapy of macitentan and tadalafil in pulmonary ar‐ 2023，9（6）：00495-02023.
terial hypertension[J]. Eur Respir J，2020，56（3）： [24] SATOH M，ASO K，NAKAYAMA T，et al. Effect of treat‐
2000673. ment with epoprostenol and endothelin receptor antago‐
[13] WANG G Z，QIN J L，HAN D. Long-term safety of maci‐ nists on the development of thyrotoxicosis in patients with
tentan in patients with pulmonary hypertension：a meta- pulmonary arterial hypertension[J]. Endocr J，2017，64
analysis of randomised controlled trials[J]. Eur J Clin In‐ （12）：1173-1180.
vest，2023，53（11）：e14059. [25] 叶小飞. 上市后药品不良反应信号检测方法的进展与思
[14] VACHIÉRY J L，DELCROIX M，AL-HITI H，et al. Maci‐ 考[J]. 海军军医大学学报，2022，43（2）：117-122.
tentan in pulmonary hypertension due to left ventricular YE X F. Progress and thinking of signal detection metho-
dysfunction[J]. Eur Respir J，2018，51（2）：1701886. dology on post-marketing adverse drug reaction surveil‐
[15] RUOPP N F，COCKRILL B A. Diagnosis and treatment lance[J]. Acad J Nav Med Univ，2022，43（2）：117-122.
of pulmonary arterial hypertension：a review[J]. JAMA， （收稿日期：2023-11-28 修回日期：2024-04-27）
2022，327（14）：1379-1391. （编辑：张元媛）

中国药房 2024年第35卷第13期 China Pharmacy 2024 Vol. 35 No. 13 · 1633 ·